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What is already known about the topic?
•• Lower limb lymphoedema (LLL) is a recognised complication of cancer and a common symptom encountered in palliative 
care worldwide, associated with reduced mobility and poor quality of life.
•• The prevalence of LLL and its best treatment in patients with cancer are unclear.
•• The efficacy of the existing treatments is unclear.
What this paper adds?
•• All included studies in the systematic review evaluated conservative treatments, including pneumatic compression devices, 
manual lymphatic drainage (MLD), compression bandages and herbal remedy combining Coumarin, Ginkgo and Melitoto 
(with or without MLD) achieved short-term reduction of limb volume.
The management of secondary lower  
limb lymphoedema in cancer patients:  
A systematic review
Elaine YL Leung1, Seema A Tirlapur1 and Catherine Meads2
Abstract
Background: Lower limb lymphoedema is a recognised complication of cancer commonly encountered in palliative care, associated 
with reduced mobility and poor quality of life.
Aim: To evaluate the available evidence for the treatment of secondary lower limb lymphoedema in patients with malignancies.
Design: A systematic review of the literature.
Data sources: The MEDLINE, Embase, LILACS, Science Citation Index, Cochrane Databases and conference proceedings for 
published data from date of inception to July 2014 were searched. Relevant unpublished studies via relevant databases, Internet 
searches and hand-searches of the bibliographies of relevant papers were performed.
Results: From 1617 citations, 32 papers were selected for full-text assessment. Two randomised trials and five observational studies 
were identified. The two randomised controlled trials evaluated graded compression stockings and Coumarin capsules, respectively. 
The five observational studies evaluated lymphovenous microsurgical shunts, pneumatic compression devices, compression bandages 
alone, manual lymphatic drainage with compression and a herbal remedy combining Coumarin, Ginkgo and Melitoto (with or without 
manual lymphatic drainage), respectively. The extracted studies showed substantial heterogeneity. Hence, a meta-analysis was 
inappropriate and not performed.
Conclusion: Few studies have evaluated the clinical effectiveness and potential side effects of treatments for lower limb lymphoedema. 
Moreover, symptoms and quality-of-life assessments were inconsistently reported. All included studies report lower limb volume 
reduction after treatment, which includes complex decongestion therapy, graded compression stockings and lymphovenous microsurgical 
shunts. Adequately powered randomised controlled trials of these interventions are recommended. Effort should be made to establish 
standardised outcomes, to minimise bias and to improve reporting quality in future trials of treatment for lower limb lymphoedema.
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•• Surgical management of LLL (lymphovenous microsurgical shunts) can be an effective treatment with long-term improve-
ments reported.
•• These studies were heterogeneous and with moderate to high risks of bias.
Implications for practice, theory or policy
•• Improving methodological quality of future studies requires minimising the risks of bias, standardising measured outcomes 
and improving reporting quality.
•• Adequately powered randomised trials of complex decongestion therapy, graded compression stockings and microvascular 
lymphovenous shunts evaluating risks, benefits and cost-effectiveness are recommended.
Background
Lower limb lymphoedema (LLL) is a recognised compli-
cation of cancers and its treatment.1–4 LLL presents as 
chronic unilateral or bilateral swelling of the lower limbs, 
which may be accompanied with pain, tissue fibrosis and 
associated skin changes (e.g. skin thickening and hyper-
pigmentation). It is associated with reduced mobility, psy-
chosexual dysfunction and poor quality of life (QoL).4–6 It 
was estimated that the majority (70%–80%) of all signifi-
cant lymphoedema referred to specialist units are cancer-
related.7,8 Moreover, more than one-third (36%) have 
lymphoedema on admission to a specialist palliative care 
unit,9 but only a few get referred to specialist lymphoe-
dema services.10 Although the commonest cause of LLL in 
developing countries is filarial infection,11 more than half 
of the new cancer cases reported worldwide were diag-
nosed in low- and middle-income countries (LMIC).12 
Patients diagnosed with cancers in LMIC often have lim-
ited access to surgery and medical and radiological man-
agement of cancer.13 Palliative care, including the 
management of LLL, is therefore an important part of 
comprehensive cancer care that should be incorporated 
early in a patient’s journey.14
The risk of LLL in cancer patients and its best manage-
ment strategy are unknown.1,3 Moreover, previous reports 
suggested that clinicians had often shown inadequate 
knowledge and lack of interest in the evidence-based man-
agement of lymphoedema,15 particularly lymphoedema 
secondary to non-breast malignancies.16–19 Standardised 
assessments of LLL exist (e.g. the International Society of 
Lymphology lymphoedema staging system10) and are rou-
tinely used by specialist management units of lymphoe-
dema.10 Clinical progress can be monitored by standardised 
pro forma including both symptomatic progress and limb 
circumference measurements.10
Physical therapies promoting lymph drainage are com-
monly used to treat lymphoedema, with varying success.10 
However, the majority of interventional studies were per-
formed on patients with upper limb lymphoedema second-
ary to breast cancer.17–19
None of the previous systematic reviews have specifi-
cally evaluated the evidence available for the treatment of 
patients with non-infective secondary LLL.16–19 This study 
systematically reviewed the current evidence for the treat-
ment of patients with LLL secondary to malignancies and 
their treatment.
Methods
This systematic review was performed in accordance with 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guideline.20
Identifications of studies
We searched the MEDLINE, Embase, LILACS, Science 
Citation Index, Cochrane Central Register of Controlled 
Trials (CENTRAL) and International Society of Lymphology 
and the Australian Lymphoedema Association congress pro-
ceedings from inception to 5 July 2014 to identify relevant 
citations. We looked for relevant unpublished studies and 
those reported in the grey literature in databases such as 
Systems for Information in Grey Literature (SIGLE). We 
looked for systematic reviews in the area to find any primary 
studies they might have included. The search term combina-
tion captured the concept ‘secondary lower limb lymphoe-
dema’ and ‘therapy’ incorporating Medical Subject Headings 
(MeSH), free text and word variants (Appendix 2, available 
online). Language restrictions were not applied.
Inclusion and exclusion criteria
Included were all randomised controlled studies with any 
number of participants, as well as comparative observa-
tional studies (cohort and case-control) with more than 50 
participants with secondary LLL. Only studies that have 
included patients with malignancies or patients who had 
undergone treatment for their malignancies were included. 
Excluded were studies of lymphatic flow, biochemical 
markers, mixed cohorts with no description of the particu-
lar effects of treatment on LLL and those exclusively on 
infective LLL and/or non-malignant (e.g. orthopaedic) 
conditions.
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Study selection
The electronic searches were scrutinised and full manu-
scripts of all citations likely to meet the predefined selec-
tion criteria were selected. Independent reviewers 
(E.Y.L.L. and S.A.T.) examined these manuscripts and 
made the final decisions regarding inclusion or exclusion. 
In cases of duplicate publications, we selected the most 
recent and complete versions.
Data extraction and assessment of the  
risks of bias
Two independent reviewers (E.Y.L.L. and S.A.T.) extracted 
data using pre-designed and piloted data extraction forms. 
The risks of bias of each study were assessed by different 
methods according to study design. Randomised con-
trolled trials (RCTs) were assessed by Jadad’s Score,21 and 
observational studies were assessed by Newcastle–Ottawa 
Scale (NOS).22,23
Results
Paper selection
From 1617 citations, 32 were deemed to be relevant for 
full-text assessment (Appendix 1, available online). Two 
randomised trials and five observational studies were 
identified after full-text assessment (Figure 1). One eligi-
ble Italian-language study was identified and translated 
by a native Italian speaker. Two studies exclusively 
included patients who had undergone gynaecological 
operations24,25 or Classic Kaposi-sarcoma.26 Other stud-
ies included patients with mixed aetiologies,27–30 that is, 
participants with malignant and non-malignant conditions. 
Unfortunately, only pooled results were available for these 
studies (Table 1). None of the studies explicitly stated the 
stages of malignancies of their participants. No LLL stud-
ies retrieved exclusively recruited participants within a 
palliative care population.
Summary of results
In total, 778 participants with LLL were included in 
seven studies (two focused on patients with gynaecologi-
cal malignancy, one on classic Kaposi lymphoma and 
four included LLL patients with different aetiologies). 
The two randomised trials evaluated graded compression 
stockings (GCSs; n = 10)24 compared to conservative 
management without GCSs (n = 8) and Coumarin cap-
sules (n = 10) compared to placebo (n = 11).27 The five 
observational studies evaluated pneumatic compression 
devices (PCDs)28 (n = 196), lymphovenous microsurgical 
shunts (LMS)29 (n = 260), manual lymphatic drainage 
(MLD) with compression (n = 65),26 compression band-
ages alone (n = 50)25 and a herbal remedy combining 
Coumarin, Ginkgo and Melitoto (with or without MLD) 
(n = 133).30 The summaries of all eligible studies are 
described in Table 1.
Different methods were used to evaluate lymphoedema, 
and only one study evaluated the impact of observer vari-
ability (Table 1).
Assessment of the risks of bias
The included studies showed substantial clinical heteroge-
neity (Table 1). Hence, a meta-analysis was inappropriate 
and not performed. In addition, the included studies also 
showed significant risks of bias. We have summarised the 
risk of bias assessments of these studies in Figure 2, and a 
detailed breakdown was described in Appendix 3, availa-
ble online.
Effects of the treatments
Different volumetric outcomes were used (Table 1). All 
included studies reported favourable outcomes of the man-
agement evaluated. GCS was reported to reduce excess 
volume by 6.9%26 and mean lower limb volumes by 
350 mL.24 PCD achieved a mean lower limb volume reduc-
tion of 8% or 1150 mL, although the range of response was 
wide.28 Complex decongestion therapy reduced the mean 
percentage excess volume by 20%.25 Herbal remedies 
including Coumarin were also reported to reduce limb cir-
cumference by 7.8%–17.6%30 and by 1.39% per month.27 
Microsurgical lymphovenous shunts consistently reduced 
the mean circumferences ratio of oedematous versus nor-
mal limb by 20%–30%.29 None of the included studies 
reported confidence intervals of their results.
Patient-reported outcomes and side effects of 
treatments
Four studies reported QoL assessments,24,25,27,28 using dif-
ferent instruments and surveys. Only two used validated 
Figure 1. PRISMA flow chart.
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QoL instruments.25,27 One of these two studies reported 
significant improvement of QoL in the treatment group, 
while the other was a pilot trial with insufficient power to 
detect any difference in QoL.
All evaluated treatments appeared to be safe, although 
three studies did not state whether side effects were specifi-
cally assessed.24,26,30 Reported side effects of physical com-
pression treatments include muscle cramps28 and limb 
erythema.28 No side effect was reported from decongestive 
physical therapy.25 Herbal remedies containing Coumarin 
was associated with mild gastrointestinal upset.27 No surgi-
cal complication was reported after LMS.29
Discussion
Main findings, strengths and limitations
All included studies reported overall volumetric and symp-
tomatic improvements of LLL after treatment, with mini-
mal side effects. Few studies24–30 have investigated the 
effects of different treatments for LLL secondary to malig-
nancies. Although it is not possible to disaggregate infor-
mation specifically in the end-of-life palliative care 
populations from the studies, our results highlight the lack 
of evidence in such population and the potential impact of 
well-designed research in this area. This systematic review 
included all randomised controlled studies and observa-
tional studies participated by patients with LLL secondary 
to malignancies. No time and language restrictions were 
applied to our literature search. A comprehensive list of 
databases, including grey literature databases, was 
searched. Moreover, previous systematic reviews only 
included conservative management of lymphoedema.17–19 
We also included a study on surgical management of LLL 
in this systematic review.29
However, the included studies showed clinical hetero-
geneity and often included participants with LLL second-
ary to different aetiologies (Table 1 and Figure 2). In 
addition, all included studies showed moderate to high 
risks of bias. As a result of these limitations, it was impos-
sible to accurately estimate the overall effect size of each 
evaluated treatment for patients with LLL, and whether 
any one treatment is superior compared to the others.
Different definitions and verification methods of LLL 
were used to identify participants (Table 1). In addition, 
various outcome measurements were used to evaluate vol-
umetric changes in these studies (Table 1). In the majority 
of studies, inter-observer and intra-observer variability of 
outcome measurements were not taken into account 
(Table 1). Although five included studies evaluated sub-
jective changes of symptoms,24,25,27,28,30 only one study29 
specifically evaluated the complications of the treatment.
Recommendations for future studies on the 
management of LLL
This review suggested that the effectiveness of the treat-
ments for LLL and their side effect profiles are currently 
unclear. Although our results provided limited evidence to 
support current clinical decision-making, the included 
studies24–30 could guide the planning of future studies.
Patients. A number of included studies recruited partici-
pants with LLL secondary to different aetiologies and 
combining patients with and without malignancies in the 
same reported cohort. It is unclear whether the aetiologies 
of lymphoedema have any implications on the response to 
treatment. For example, in malignancies, lymphoedema 
can be secondary to both the tumours and their surgical 
treatment. Studies evaluating the effects of treatment on 
clinically relevant subgroups will be helpful.
Multiple diagnostic criteria were used to define lym-
phoedema in the included studies, and often, they were not 
clearly defined (Table 1). Grading systems for the diagno-
sis of lymphoedema exist10 and should be used in future 
studies.
Interventions and comparison. Although the pharmacological 
interventions used were well described, studies using other 
interventions such as GCSs and PCDs provided insufficient 
methodological details for replication in different popula-
tions. In the included case-control studies, information 
about the control was limited and potential confounding fac-
tors could not be satisfactorily evaluated. Sufficient meth-
odological details are needed in future studies.
Outcomes. Only two out of the seven included studies used 
the same volumetric outcomes (Table 1). Moreover, each 
study used a different method to measure the limbs, and 
only one study considered observer variability (Table 1). 
Figure 2. Assessment of the risks of bias: (a) randomised 
controlled trial assessed by Jadad’s Score21 and (b) 
observational studies assessed by Newcastle–Ottawa Scale.22,23
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The results between these studies were difficult to com-
pare and impossible to combine.
In addition, it is established that immobility leads to 
morbidities and mortalities through complications such as 
infection and thromboembolism. Since LLL can lead to 
reduced mobility, there may be additional adverse effects 
secondary to LLL that are clinically important. None of the 
included studies had evaluated these risks. Moreover, the 
potential side effects of the treatment for LLL have not 
been evaluated in the existing studies. Finally, long-term 
outcomes of lymphoedema treatment have rarely been 
investigated.17–19
In 2010, the Core Outcome Measures in Effectiveness 
Trials (COMET) initiative was launched to develop agreed 
standardised sets of outcomes to represent the minimum 
set that should be measured and reported in all randomised 
trials of a specific condition.31 We believe core outcomes 
set should be developed for future trials of LLL. The pro-
posed core outcomes set should not simply focus on volu-
metric measurements by trained assessors (to reduce 
inter-observer and intra-observer variability). It should 
also assess side effects of the evaluated treatment, compli-
cations of LLL (including fibrosis and incidence of deep 
vein thrombosis) and use validated instruments to assess 
pain and QoL of participants.
Study design. RCT is the most appropriate primary study 
design to evaluate an intervention.32 However, only two 
ongoing clinical trials on the treatment of LLL have been 
registered – one is investigating a new PCD33 and the other 
is evaluating pelvic and lower extremity exercises.34 Suf-
ficiently powered randomised trials using standardised 
assessment of LLL and validated outcome measures are 
needed for improving the treatment of LLL.
Reporting of future studies. It is recognised that RCTs or 
controlled trials are often not available.35 Observational 
studies with comparators are acceptable study designs to 
evaluate the effects of an intervention. The reporting qual-
ity of the observational studies included in this review was 
poor, which made the assessment of the risks of bias 
difficult.
Similar to the Consolidated Standards of Reporting 
Trials (CONSORT) statement36 for reporting clinical tri-
als, recommendations also exist for the reporting of obser-
vational studies. The STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) initia-
tive37 helps support the reporting of observational studies 
by encouraging comprehensive description of methodol-
ogy, recognition and reporting of bias and limitations and 
inclusion of numeric data and unadjusted estimates. We 
believe the adoption of STROBE can help readers to deter-
mine the impact of bias and confounders of studies, as well 
as allowing appropriate secondary data analysis (e.g. meta-
analysis) of similar studies.
Conclusion
Few studies have evaluated the clinical effectiveness and 
potential side effects of treatments for LLL, a common 
and disabling symptom in palliative care not only 
restricted to those who are at the end of life. All studies to 
date report a reduction of lower limb volume after treat-
ment, but symptom and QoL assessments were inconsist-
ently reported. In this review, complex decongestion 
therapy, GCSs and LMSs have been shown to produce 
larger reduction of limb volume. Adequately powered 
RCTs of these interventions are recommended. Effort 
should also be made to establish standardised outcomes, 
to minimise bias and to improve reporting quality in 
future trials of treatment for LLL.
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